Lanean...
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations
Imatinib is an inhibitor of the Abl tyrosine kinase domain that is effective in the treatment of chronic myelogenic leukemia (CML). Although imatinib binds tightly to the Abl kinase domain, its affinity for the closely related kinase domain of c-Src is at least 2000-fold lower. Imatinib recognition...
Gorde:
| Egile Nagusiak: | , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2009
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2678021/ https://ncbi.nlm.nih.gov/pubmed/19276351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-08-3953 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|